BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7495747)

  • 1. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC.
    Liang MN; Beeson C; Mason K; McConnell HM
    Int Immunol; 1995 Sep; 7(9):1397-404. PubMed ID: 7495747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
    Bangia N; Watts TH
    Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
    Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
    J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
    Honey K; Forbush K; Jensen PE; Rudensky AY
    J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
    Wu S; Gorski J
    Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecules.
    Weenink SM; Milburn PJ; Gautam AM
    Int Immunol; 1997 Feb; 9(2):317-25. PubMed ID: 9040013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
    Kropshofer H; Vogt AB; Hämmerling GJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
    Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
    J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II.
    Sette A; Southwood S; Miller J; Appella E
    J Exp Med; 1995 Feb; 181(2):677-83. PubMed ID: 7836921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP).
    Zhong G; Castellino F; Romagnoli P; Germain RN
    J Exp Med; 1996 Nov; 184(5):2061-6. PubMed ID: 8920896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-release of CLIP in peptide loading of HLA-DR molecules.
    Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
    Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif.
    Zhu Y; Rudensky AY; Corper AL; Teyton L; Wilson IA
    J Mol Biol; 2003 Feb; 326(4):1157-74. PubMed ID: 12589760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
    Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
    J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
    Hitzel C; Koch N
    Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
    Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
    Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.